Revumenib vs Ziftomenib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: Menin · full Acute Myeloid Leukemia pipeline
Revumenib
Marketed by Syndax
NCT04065399 · Phase 1/2 · recruiting
All participants received revumenib in open-label dose-escalation and expansion cohorts, with no randomization and no comparison arm. The remission rate was tested only against a fixed benchmark rate, not against patients given another treatment, so the study cannot show how revumenib compares with alternatives.
Next expected readout: December 2026 · NCT05360160 (registry estimate)
No aligned efficacy figure on record for this race.
Ziftomenib
Marketed by Kura Oncology, Inc. and partners
NCT04067336 · Phase 1/2 · active, not recruiting
All phase 2 participants received ziftomenib in an open-label single group, with no blinding and no comparison arm; the only randomization was between two doses in an earlier dose-finding phase. The remission rate was tested against a fixed benchmark rate rather than against patients given another treatment, so the study cannot show how ziftomenib compares with alternatives.
Next expected readout: December 2026 · NCT06001788 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Revumenib | Ziftomenib |
|---|---|---|
| OS, median | —Trial running · NCT03013998 | —Trial running · NCT07007312 |
| Complete remission | —Trial running · NCT03013998 | —Trial running · NCT07007312 |
| Event-free survival, median | —Trial running · NCT03013998 | —Trial running · NCT07007312 |
| Duration of response, median | —Trial running · NCT03013998 | —Trial running · NCT07007312 |
OS, median
- Revumenib
- —Trial running · NCT03013998
- Ziftomenib
- —Trial running · NCT07007312
Complete remission
- Revumenib
- —Trial running · NCT03013998
- Ziftomenib
- —Trial running · NCT07007312
Event-free survival, median
- Revumenib
- —Trial running · NCT03013998
- Ziftomenib
- —Trial running · NCT07007312
Duration of response, median
- Revumenib
- —Trial running · NCT03013998
- Ziftomenib
- —Trial running · NCT07007312
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Revumenib: no structured comparison results are available for Acute Myeloid Leukemia.
Ziftomenib: no structured comparison results are available for Acute Myeloid Leukemia.
Acute Lymphoblastic Leukemia
Shared mechanism: Menin · full Acute Lymphoblastic Leukemia pipeline
Revumenib
Marketed by Syndax
NCT04065399 · Phase 1/2 · recruiting
All participants received revumenib in open-label dose-escalation and expansion cohorts, with no randomization and no comparison arm. The remission rate was tested only against a fixed benchmark rate, not against patients given another treatment, so the study cannot show how revumenib compares with alternatives.
Next expected readout: December 2027 · NCT04065399 (registry estimate)
No aligned efficacy figure on record for this race.
Ziftomenib
Marketed by Kura Oncology, Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2028 · NCT04067336 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Acute Lymphoblastic Leukemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Revumenib: no structured comparison results are available for Acute Lymphoblastic Leukemia.
Ziftomenib: no structured comparison results are available for Acute Lymphoblastic Leukemia.
Relapsed/Refractory Acute Myeloid Leukemia
Shared mechanism: Menin · full Relapsed/Refractory Acute Myeloid Leukemia pipeline
Revumenib
Marketed by Syndax
NCT04065399 · Phase 1/2 · recruiting
All participants received revumenib in open-label dose-escalation and expansion cohorts, with no randomization and no comparison arm. The remission rate was tested only against a fixed benchmark rate, not against patients given another treatment, so the study cannot show how revumenib compares with alternatives.
Next expected readout: January 2027 · NCT06177067 (registry estimate)
No aligned efficacy figure on record for this race.
Ziftomenib
Marketed by Kura Oncology, Inc. and partners
NCT04067336 · Phase 1/2 · active, not recruiting
All phase 2 participants received ziftomenib in an open-label single group, with no blinding and no comparison arm; the only randomization was between two doses in an earlier dose-finding phase. The remission rate was tested against a fixed benchmark rate rather than against patients given another treatment, so the study cannot show how ziftomenib compares with alternatives.
Next expected readout: December 2026 · NCT06001788 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Relapsed/Refractory Acute Myeloid Leukemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Revumenib: no structured comparison results are available for Relapsed/Refractory Acute Myeloid Leukemia.
Ziftomenib: no structured comparison results are available for Relapsed/Refractory Acute Myeloid Leukemia.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Revumenib's landscape · Ziftomenib's landscape